Roivant Sciences Ltd.
ROIV
Kedudukan dalam Saham
#978
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Harga Saham
$33.73
Disegerakkan terakhir: 2026-07-31
Modal Pasaran
$24.37B
Perubahan (1 hari)
-2.28%
Perubahan (1 tahun)
90.15%
Negara
GB
Perdagangan Roivant Sciences Ltd. (ROIV)
Kategori
Healthcare
Pendapatan untuk Roivant Sciences Ltd. (ROIV)
Pendapatan pada Jun 2026 TTM: $-289.88M
Menurut laporan kewangan terkini Roivant Sciences Ltd., pendapatan semasa syarikat ialah $-289.88M. Pada tahun 2024, syarikat memperoleh pendapatan sebanyak $4.57B, peningkatan berbanding pendapatan pada tahun 2023 yang berjumlah $-1.22B. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Roivant Sciences Ltd. dari 2020 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-289.88M | -57.47% |
| 2025 | $-681.59M | -114.92% |
| 2024 | $4.57B | -472.94% |
| 2023 | $-1.22B | 32.59% |
| 2022 | $-923.75M | 2.80% |
| 2021 | $-898.55M | 60.17% |
| 2020 | $-560.99M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | -1,919.68% |
US
|
|
| $-3.09B | 964.92% |
US
|
|
| $-4.02B | 1,285.47% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -772.92% |
NL
|
